Myeloproliferative Disorders
"Myeloproliferative Disorders" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
| Descriptor ID |
D009196
|
| MeSH Number(s) |
C15.378.190.636
|
| Concept/Terms |
Myeloproliferative Disorders- Myeloproliferative Disorders
- Disorder, Myeloproliferative
- Disorders, Myeloproliferative
- Myeloproliferative Disorder
|
Below are MeSH descriptors whose meaning is more general than "Myeloproliferative Disorders".
Below are MeSH descriptors whose meaning is more specific than "Myeloproliferative Disorders".
This graph shows the total number of publications written about "Myeloproliferative Disorders" by people in this website by year, and whether "Myeloproliferative Disorders" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1998 | 1 | 0 | 1 |
| 1999 | 3 | 0 | 3 |
| 2001 | 0 | 1 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 5 | 1 | 6 |
| 2004 | 2 | 0 | 2 |
| 2005 | 2 | 1 | 3 |
| 2006 | 9 | 2 | 11 |
| 2007 | 7 | 0 | 7 |
| 2008 | 7 | 1 | 8 |
| 2009 | 6 | 1 | 7 |
| 2010 | 14 | 1 | 15 |
| 2011 | 10 | 1 | 11 |
| 2012 | 10 | 2 | 12 |
| 2013 | 7 | 5 | 12 |
| 2014 | 13 | 1 | 14 |
| 2015 | 14 | 2 | 16 |
| 2016 | 10 | 2 | 12 |
| 2017 | 13 | 1 | 14 |
| 2018 | 16 | 0 | 16 |
| 2019 | 14 | 0 | 14 |
| 2020 | 10 | 3 | 13 |
| 2021 | 19 | 1 | 20 |
| 2022 | 22 | 0 | 22 |
| 2023 | 20 | 0 | 20 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myeloproliferative Disorders" by people in Profiles.
-
Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms. Cancer Med. 2024 Mar; 13(5):e7093.
-
Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. Clin Lymphoma Myeloma Leuk. 2024 04; 24(4):e130-e137.
-
Optical Genome Mapping Helps to Identify BCR::JAK2 Rearrangement Arising from Cryptic Complex Chromosomal Aberrations: A Case Report and Literature Review. Genes (Basel). 2023 Dec 08; 14(12).
-
Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms. Mod Pathol. 2024 Feb; 37(2):100397.
-
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis. Blood Adv. 2023 11 28; 7(22):7007-7016.
-
Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms. Pathobiology. 2024; 91(1):45-54.
-
Guide to the Diagnosis of Myeloid Neoplasms: A Bone Marrow Pathology Group Approach. Am J Clin Pathol. 2023 10 03; 160(4):365-393.
-
Reappraisal of cardiovascular risk factors in patients with chronic myeloproliferative neoplasms. Clin Adv Hematol Oncol. 2023 Oct; 21(10):541-548.
-
Frontline Hyper-CVAD Plus Venetoclax for Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm. J Pediatr Hematol Oncol. 2023 11 01; 45(8):e1001-e1004.
-
Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. Leukemia. 2023 09; 37(9):1767-1778.